Investors may believe Sichuan Goldstone Asia Pharmaceutical Inc.'s strong earnings growth could underperform the market, causing its low P/E ratio. If recent earnings trends persist, a significant share price rise seems unlikely.
Sichuan Goldstone Asia Pharmaceutical's shift to profitability has likely led to a more positive market perception, evidenced by its share price growth. The overall sentiment around the company appears to have recently improved considering the increased total shareholder return (TSR).
Sichuan Goldstone Stock Forum
No comment yet